Table 6 Selected treatment emergent adverse events (TEAE, Safety population = 28 patients) in Cohort C (HR+ HER2low).
% Any TEAE (95% CI) | % Grade 3 TEAE (95% CI) | |
|---|---|---|
Diarrhea | 53.6 (33.9−72.5) | 7.1 (0.9−23.5) |
Neutropenia | 50.0 (30.6−69.4) | 42.9 (24.5−62.8) |
Stomatitis | 28.6 (13.2−48.7) | 3.6 (0.1−18.3) |
Mucosal inflammation | 25.0 (10.7−44.9) | 7.1 (0.9−23.5) |
Pyrexia | 25.0 (10.7−44.9) | − |
Aphthous ulcer | 14.3 (4.0−32.7) | − |
Headache | 14.3 (4.0−32.7) | − |
Asthenia | 10.7 (2.3−28.2) | − |
Fatigue | 10.7 (2.3−28.2) | − |
Nausea | 10.7 (2.3−28.2) | − |
Leukopenia | 10.7 (2.3−28.2) | 3.6 (0.1−18.3) |
Arthralgia | 10.7 (2.3−28.2) | − |
Dyspepsia | 10.7 (2.3−28.2) | − |
Hot flush | 10.7 (2.3−28.2) | − |
Hypertension | 10.7 (2.3−28.2) | − |
Anemia | 7.1 (0.9−23.5) | − |
ALT increased | 7.1 (0.9−23.5) | − |
AST increased | 7.1 (0.9−23.5) | 3.6 (0.1−18.3) |
LVEF decrease | 3.6 (0.1−18.3) | − |
